EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIP

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...

Related Keywords

Ukraine , United States , Russia , America , Jessica Breu , Daniel Vitt , Edna Kaplan , Paula Schwartz , Andreas Muehler , Exchange Commission , Immunic Inc , Nasdaq , Distribution Services , Rx Communications Group , Completes Enrollment , Its Phase , Vidofludimus Calcium , Progressive Multiple Sclerosis , Progressive Multiple , Unblinded Interim Biomarker Analysis Expected , Full Data Readout Expected , Chief Executive Officer , Chief Medical Officer , North America , Eastern Europe , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Corporate News , Regulatory Announcements , Its , Hase , Calliper , Trial , Idofludimus , Calcium , Progressive , Multiple , Clerosis , Et Cest , The , Ompletes , Enrollment , P ,